Celixir

Official Twitter for Celixir World-Class #scientists and #biotechnology leadership is devoted to discovering breakthrough regenerative Stem Cell #medicines.

[Celixir @CelixirLtd]

Nobel Prize Winner - Professor Sir Martin Evans is the co-founder of @CelixirLtd
#stemcells #nobelprizewinner #regenerative #medicine #science #news

[Celixir @CelixirLtd]

A fascinating read about a promising cell therapy for RPE (Retinal Pigment Epithelium) degeneration such as in age related macular degeneration.
https://t.co/Fmyxzb1ZAX

[Celixir @CelixirLtd]

An interesting article discussing a newly formed joint undertaking in Morphological Profiling with Cell Painting
https://t.co/O7fjnCoYuW

[Celixir @CelixirLtd]

This study looks at investigating karyotype and genome size of tick cell lines.
https://t.co/l0skMjt01K

[Celixir @CelixirLtd]

This interesting study looks at aiming to repair pathogenic allele-specific single-nucleotide mutations using a single round of genome editing.
https://t.co/NJUGXaLzIx

[Celixir @CelixirLtd]

The European Medicines Agency (EMA) has agreed to review a request to approve the investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), for people with pretreated lymphomas.

https://t.co/rmrMY141uq

[Celixir @CelixirLtd]

CAR T-cell therapy, Tecartus, granted FDA approval for Mantle Cell Lymphoma
https://t.co/EWmjNbLYrn

[Celixir @CelixirLtd]

CAR-T cells are promising for the treatment of cancer but their side effects are a concern. In this study, a team has developed a new CAR T-cell immunotherapy strategy that uses light to activate the immune cells specifically in cancerous regions.
https://t.co/8kFrfCQYcW

[Celixir @CelixirLtd]

The long-term effects of immune checkpoint inhibitors, PD-1 and PD-L1 inhibitors, in cancer treatment are encouraging
https://t.co/55i5P0gdPh

[Celixir @CelixirLtd]

Recombinant canstatin seems to reduce heart damage after heart attacks.
https://t.co/ZeBvE6YAoT

[Celixir @CelixirLtd]

Scorpion toxins may be helpful in treating heart attacks.
https://t.co/cEh81tBgSu

[Celixir @CelixirLtd]

3D printing allows the formation of a working heart pump from human heart cells and is another step towards artificial hearts. https://t.co/wEmgXSCQ8f

[Celixir @CelixirLtd]

Eating lots of protein, especially plant protein, is associated with a lower risk of death from any cause.
https://t.co/SP40RuH982

[Celixir @CelixirLtd]

This study shows the safety and efficacy of dopaminergic progenitors (DAPs) derived from a clinical-grade human iPSC line. These cells have the potential to replace damaged neurons in Parkinson’s disease.

https://t.co/DD0aXHM4X6

[Celixir @CelixirLtd]

This study identifies roles of autophagy in embryonic stem cell renewal and differentiation and presents an opportunity for new regenerative medicines.

https://t.co/wFeU6XepB4

[Celixir @CelixirLtd]

This review discusses using humanized mice to test anti-cancer therapies.
https://t.co/JU7zbZ4w5B

[Celixir @CelixirLtd]

An interesting approach to bone implant biomaterials.
https://t.co/Mmd3hhBRPh

[Celixir @CelixirLtd]

A brief discussion of the essential safety considerations for cell and gene therapies.
https://t.co/wUsRiNLbbp

[Celixir @CelixirLtd]

A nice summary of terminology relating to advanced therapy medicinal products (ATMPs), including gene and cell-based therapies, tissue-engineered products, and combined ATMPs.

https://t.co/2s9EezyPlw

[Celixir @CelixirLtd]

The U.S. Food and Drug Administration (FDA) restarting on-site inspections based on a COVID-19 Advisory Rating system (COVID-19 Advisory Level).

https://t.co/IRbHOAQLvN

[Celixir @CelixirLtd]

The Medicines and Healthcare products Regulatory Agency (MHRA) is making careful preparations for a safe return to normal UK on-site Good Practice (GxP) inspection scheduling.

https://t.co/kBuuZuZr1Z